This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips
by Zacks Equity Research
VKTX's first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end.
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
by Zacks Equity Research
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
by Zacks Equity Research
Valneva intends to test its experimental Shigella vaccine in nearly 110 infants. Results from this study are expected later this year.
VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe
by Zacks Equity Research
With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
by Zacks Equity Research
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study
by Zacks Equity Research
Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?
by Zacks Equity Research
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda
by Zacks Equity Research
The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at least as effective as the IV version.
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
by Zacks Equity Research
The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
by Zacks Equity Research
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Creative Medical Technology Holdings, Inc. (CELZ) and 89BIO (ETNB) have performed compared to their sector so far this year.
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
by Zacks Equity Research
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
by Zacks Equity Research
ELEV decides to stop developing its lead drug after disappointing data from an early-stage study evaluating its sole clinical-stage drug in gastric cancers.
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
by Zacks Equity Research
AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
by Zacks Equity Research
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now
by Zacks Equity Research
89BIO (ETNB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
FDA Accepts RHHBY's sNDA for Gazyva in Treating Lupus Nephritis
by Zacks Equity Research
Roche's filing is based on data from a late-stage study that shows a complete renal response benefit in lupus nephritis patients who received Gazyva.
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
by Zacks Equity Research
Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.
Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y
by Zacks Equity Research
PRGO reports mixed Q4 2024 results. The decline in the company's top line is due to the loss of sales stemming from exited businesses and product lines.
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
by Zacks Equity Research
Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Should You Buy 89BIO (ETNB) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 219.1% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
by Zacks Equity Research
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.